Wesley Armstrong (@wes_armstrong_) 's Twitter Profile
Wesley Armstrong

@wes_armstrong_

MD PhD Student, UCLA-Caltech MSTP

ID: 1522673967269437440

calendar_today06-05-2022 20:25:51

12 Tweet

20 Followers

46 Following

Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

PSMA PET findings in an “EMBARK-like” cohort of HR nmHSPC Wesley Armstrong Jeremie Calais 📌 n=183 📌 med PSA: 2.4 (RP), 6.9 (dRT), 2.7 (RP+SRT), 2.8 (overall pop) 📌 PSMA PET+: 85.2%; 609 PSMA PET+ lesions; 3.9 mean number of lesions/case. 46% M1 dx! UroToday.com #ASCO23

PSMA PET findings in an “EMBARK-like” cohort of HR nmHSPC <a href="/Wes_Armstrong_/">Wesley Armstrong</a> <a href="/CalaisJeremie/">Jeremie Calais</a> 

📌 n=183
📌 med PSA: 2.4 (RP), 6.9 (dRT), 2.7 (RP+SRT), 2.8 (overall pop)
📌 PSMA PET+: 85.2%; 609 PSMA PET+ lesions; 3.9 mean number of lesions/case. 46% M1 dx!

<a href="/urotoday/">UroToday.com</a> #ASCO23
UroToday.com (@urotoday) 's Twitter Profile Photo

PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong UCLA-Caltech MSTP. #ASCO23 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/45CFtHM ASCO

PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong <a href="/uclacaltechmstp/">UCLA-Caltech MSTP</a>. #ASCO23 written coverage by <a href="/zklaassen_md/">Zach Klaassen</a> <a href="/GACancerCenter/">Georgia Cancer Center</a> &gt; bit.ly/45CFtHM <a href="/ASCO/">ASCO</a>
UroToday.com (@urotoday) 's Twitter Profile Photo

PSMA PET guided salvage radiotherapy among patients with #ProstateCancer in the post-prostatectomy setting: a single center posthoc analysis. Presented by Jeremie Calais .. #ASCO23 written coverage by Rashid K. Sayyid University of Toronto > bit.ly/3CbYt2w ASCO

PSMA PET guided salvage radiotherapy among patients with #ProstateCancer in the post-prostatectomy setting: a single center posthoc analysis. Presented by <a href="/CalaisJeremie/">Jeremie Calais</a> <a href="/UCLAJCCC/">.</a>. #ASCO23 written coverage by <a href="/RKSayyid/">Rashid K. Sayyid</a> <a href="/UofT/">University of Toronto</a> &gt; bit.ly/3CbYt2w <a href="/ASCO/">ASCO</a>
UroToday.com (@urotoday) 's Twitter Profile Photo

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. Presented by Djaïleb Loïc UCLA Theranostics > bit.ly/45OjzBF Zach Klaassen #ASCO23

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial. Presented by <a href="/DjailebLoic/">Djaïleb Loïc</a> <a href="/UCLATheranostic/">UCLA Theranostics</a> &gt; bit.ly/45OjzBF <a href="/zklaassen_md/">Zach Klaassen</a> #ASCO23
Jeremie Calais (@calaisjeremie) 's Twitter Profile Photo

The #UCLA Nuclear Medicine Clinical Research Team presented 7 abstracts on PSMA-PET/CT at #ASCO23. Little by little, we try to learn and share how to interpret and use the PSMA-PET information for Optimizing Treatment Decision-Making. ascopubs.org/doi/10.1200/AD…

The #UCLA Nuclear Medicine Clinical Research Team presented 7 abstracts on PSMA-PET/CT at #ASCO23. Little by little, we try to learn and share how to interpret and use the PSMA-PET information for Optimizing Treatment Decision-Making.
ascopubs.org/doi/10.1200/AD…
. (@uclajccc) 's Twitter Profile Photo

New study led by UCLA & UCSF finds PSMA PET, a molecular imaging tool, can provide prognostic information before treatment begins that can predict if the patient will have a high risk for prostate cancer returning after surgery. uclahealth.org/news/psma-pet-…

Jeremie Calais (@calaisjeremie) 's Twitter Profile Photo

Follow-up of the surgical cohort of the Pivotal Trial used for the FDA approval of 68Ga-PSMA-11 PET in European Urology: Pre-surgical PSMA-PET is a strong prognostic biomarker improving pre-operative BCR-FS risk assessment. sciencedirect.com/science/articl… x.com/UCLAJCCC/statu…

Follow-up of the surgical cohort of the Pivotal Trial used for the FDA approval of 68Ga-PSMA-11 PET in <a href="/EUplatinum/">European Urology</a>: Pre-surgical PSMA-PET is a strong prognostic biomarker improving pre-operative BCR-FS risk assessment.
sciencedirect.com/science/articl…
x.com/UCLAJCCC/statu…